Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q3 2024 earnings summary

13 Jun, 2025

Executive summary

  • Revenue for the nine months ended September 30, 2024, reached ₪1,643 million, up 31.8% year-over-year, driven mainly by growth in the logistics division.

  • Net income for the period was ₪11.9 million, compared to ₪727 thousand in the same quarter last year.

  • The board approved a dividend distribution of ₪10 million in November 2024, following two previous dividends of ₪15 million each earlier in the year.

  • A new strategic plan was adopted in August 2024, focusing on customer partnerships, growth engines, operational efficiency, and innovation.

  • No material negative impact identified from Israel's credit rating downgrades amid ongoing regional conflict.

Financial highlights

  • Gross profit for the nine months was ₪169.2 million, up from ₪130.6 million year-over-year.

  • Adjusted EBITDA for the nine months was ₪113.4 million, up from ₪91.1 million year-over-year.

  • Operating cash flow for the nine months was ₪200 million, compared to ₪214 million in the prior year.

  • Total assets as of September 30, 2024, were ₪2,789 million, with equity of ₪393 million.

  • EPS for the nine months was ₪0.023, compared to ₪0.003 in the same period last year.

Outlook and guidance

  • Management continues to monitor the impact of the regional security situation but does not foresee material adverse effects on operations.

  • The company is implementing its new strategic plan, with ongoing evaluation of business activities for alignment.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more